Northern regional event following success of our London Event in November 2025.

NHSE estimates that 2.8 million patients are eligible for weight-loss drug tirzepatide (Mounjaro) accounting for 18% of GP appointment time in 12 years time when fully rolled out.

BSLM Consensus Statement: Anti-Obesity Medications - British Society of Lifestyle Medicine

AOMs such as the GLP-1 Receptor Agonists and dual GLP-1/GIP agents have emerged as effective treatments for obesity. Whilst there is an urgent need to improve care for people with obesity, particularly to address stigmatising beliefs around the condition, we are concerned that the planned roll-out of AOMs may not be safe, effective or sustainable for the following reasons:

An over-focus on AOMs risks distracting public health efforts to tackle the root causes of obesity, namely poverty1 and a broken food system2. This approach could also risk an arms race between pharmaceuticals designed to reduce appetite and the food industry creating food to over-ride natural satiety mechanisms3.

Restricting appetite through AOMs without individually tailored wraparound support, risks unintended harms such as worsening malnutrition (including muscle wasting/sarcopenia) for the most vulnerable. People with obesity, particularly those facing food insecurity, already have high rates of vitamin and mineral deficiencies4 which can be exacerbated by restrictive food intake.

There are significant workload implications for primary care teams particularly with insufficient wraparound support.5 Primary care is already facing significant pressure from the increase rates of chronic disease, reductions in funding, a shift of care into community and a need to deliver preventive care.

Audience: This study day is intended to be an introduction and guideline for all healthcare professionals and reflects the increasing need for familiarity with weight management approaches, as they become more widespread. For those aiming to directly support individuals with weight management, look out for our upcoming e-learning course which will go into more detail.

CPD: This study offers 7hrs CPD. This is an in-person only event and there will not be a recording. We look forward to having you present and connecting with you on the day

Contact the host of Lifestyle Medicine for Weight Management: for support with or without GLP1 treatment